Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology™

Mary B. Daly, Jennifer E. Axilbund, Eileen Bryant, Saundra Buys, Charis Eng, Susan Friedman, Laura J. Esserman, Carolyn D. Farrell, James M. Ford, Judy E. Garber, Joanne M. Jeter, Wendy Kohlmann, Patrick M. Lynch, P. Kelly Marcom, Lisle M. Nabell, Kenneth Offit, Raymond U. Osarogiagbon, Boris Pasche, Gwen Reiser, Rebecca SutphenJeffrey N. Weitzel

Research output: Contribution to journalArticlepeer-review

Abstract

Recent advances in molecular genetics have identified several genes associated with inherited susceptibility to cancer and have provided a means to begin identifying individuals and families with an increased risk of cancer. This rapid expansion of knowledge about cancer genetics has implications for all aspects of cancer management, including prevention, screening, and treatment. These guidelines specifically address hereditary breast/ovarian cancer syndrome (HBOC), Li-Fraumeni syndrome, and Cowden syndrome. These guidelines were developed understanding that much of our knowledge of how the rapidly emerging field of molecular genetics can be applied clinically is preliminary and that flexibility is needed when applying these guidelines to individual families.

Original languageEnglish (US)
Pages (from-to)156-176
Number of pages21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume4
Issue number2
StatePublished - Feb 2006

Keywords

  • BRCA1
  • BRCA2
  • Breast/ovarian cancer syndrome
  • Cowden syndrome
  • Gene
  • Genetic counseling
  • Genetic risk assessment
  • Hereditary
  • Li-Fraumeni syndrome
  • NCCN Clinical Practice Guidelines

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology™'. Together they form a unique fingerprint.

Cite this